Nuvig Therapeutics Inc.

Also in BioCentury’s weekly Venture Report: Formela stepping back from Atlas’ new fund, nine-digit rounds for Nuvig and Maze, and more

Plus: leadership changes at Valo and more from Mirum, Arvinas, Vaxcyte, Lantern and Inhibikase

Plus: Grabulovski takes over as CEO of Araris and updates from IGM, Odyssey, Alpine, Nuvig, Rome, Saghmos, Nature’s Toolbox and Myricx

Plus: Albers joins Atlas, new CBO at Altimmune and updates from Nuvig, Zymeworks, Fulcrum, Step, Charm, Kymera and more

Plus new CFO at Toragen and Sinclair joins Arvinas as SVP of corporate operations

Backed by Novo Holdings and Platanus, Nuvig is designing proteins to selectively suppress active immune pathways